BR112014000665B8 - composto, composição farmacêutica, agente antimicrobiano, e, uso de um composto - Google Patents

composto, composição farmacêutica, agente antimicrobiano, e, uso de um composto Download PDF

Info

Publication number
BR112014000665B8
BR112014000665B8 BR112014000665A BR112014000665A BR112014000665B8 BR 112014000665 B8 BR112014000665 B8 BR 112014000665B8 BR 112014000665 A BR112014000665 A BR 112014000665A BR 112014000665 A BR112014000665 A BR 112014000665A BR 112014000665 B8 BR112014000665 B8 BR 112014000665B8
Authority
BR
Brazil
Prior art keywords
compound
atom
pharmaceutical composition
antimicrobial agent
optionally substituted
Prior art date
Application number
BR112014000665A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014000665B1 (pt
BR112014000665A2 (pt
Inventor
Oka Daisuke
Ye Fangguo
Miyamoto Hisashi
Cheng Jay-Fei
Sun Jiangqin
Abudusaimi Mamuti
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112014000665A2 publication Critical patent/BR112014000665A2/pt
Publication of BR112014000665B1 publication Critical patent/BR112014000665B1/pt
Publication of BR112014000665B8 publication Critical patent/BR112014000665B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014000665A 2011-08-31 2012-08-30 composto, composição farmacêutica, agente antimicrobiano, e, uso de um composto BR112014000665B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2011/001477 2011-08-31
CN2011001477 2011-08-31
CN2012001044 2012-08-06
CNPCT/CN2012/001044 2012-08-06
PCT/CN2012/080753 WO2013029548A1 (en) 2011-08-31 2012-08-30 Quinolone compound

Publications (3)

Publication Number Publication Date
BR112014000665A2 BR112014000665A2 (pt) 2017-01-10
BR112014000665B1 BR112014000665B1 (pt) 2020-02-18
BR112014000665B8 true BR112014000665B8 (pt) 2020-03-10

Family

ID=47755336

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000665A BR112014000665B8 (pt) 2011-08-31 2012-08-30 composto, composição farmacêutica, agente antimicrobiano, e, uso de um composto

Country Status (30)

Country Link
US (7) US9067887B2 (cg-RX-API-DMAC10.html)
EP (2) EP3318557A3 (cg-RX-API-DMAC10.html)
JP (4) JP6106174B2 (cg-RX-API-DMAC10.html)
KR (3) KR20140139132A (cg-RX-API-DMAC10.html)
CN (3) CN105712976A (cg-RX-API-DMAC10.html)
AR (1) AR087747A1 (cg-RX-API-DMAC10.html)
AU (2) AU2012303954B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014000665B8 (cg-RX-API-DMAC10.html)
CA (1) CA2845459C (cg-RX-API-DMAC10.html)
CO (1) CO6920292A2 (cg-RX-API-DMAC10.html)
CY (1) CY1120066T1 (cg-RX-API-DMAC10.html)
DK (1) DK2751083T3 (cg-RX-API-DMAC10.html)
EA (2) EA030867B1 (cg-RX-API-DMAC10.html)
ES (1) ES2660973T3 (cg-RX-API-DMAC10.html)
HK (2) HK1226077A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20180483T1 (cg-RX-API-DMAC10.html)
HU (1) HUE036301T2 (cg-RX-API-DMAC10.html)
IL (1) IL230559B (cg-RX-API-DMAC10.html)
LT (1) LT2751083T (cg-RX-API-DMAC10.html)
MX (3) MX394239B (cg-RX-API-DMAC10.html)
MY (1) MY165004A (cg-RX-API-DMAC10.html)
NO (1) NO2751083T3 (cg-RX-API-DMAC10.html)
PH (1) PH12014500130B1 (cg-RX-API-DMAC10.html)
PL (1) PL2751083T3 (cg-RX-API-DMAC10.html)
PT (1) PT2751083T (cg-RX-API-DMAC10.html)
SG (3) SG10201606932TA (cg-RX-API-DMAC10.html)
SI (1) SI2751083T1 (cg-RX-API-DMAC10.html)
TW (3) TWI583680B (cg-RX-API-DMAC10.html)
WO (1) WO2013029548A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201402326B (cg-RX-API-DMAC10.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3312176A1 (en) * 2011-02-01 2018-04-25 Emergent Product Development Gaithersburg Inc. Antimicrobial 4-oxoquinolizines
HRP20180483T1 (hr) * 2011-08-31 2018-05-04 Otsuka Pharmaceutical Co., Ltd. Spoj kinolona
EA035469B1 (ru) * 2013-03-15 2020-06-22 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
AR096135A1 (es) 2013-05-02 2015-12-09 Actelion Pharmaceuticals Ltd Derivados de la quinolona
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
SMT202000133T1 (it) 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Betタンパク質阻害剤として用いるための三環式複素環化合物
WO2016087615A1 (en) 2014-12-04 2016-06-09 Procomcure Biotech Gmbh Novel imidazole-based heterocyclic compounds
ES2859674T3 (es) 2014-12-04 2021-10-04 Procomcure Biotech Gmbh Agentes antimicrobianos a base de imidazol
US10570152B2 (en) * 2015-07-28 2020-02-25 Vyome Therapeutics Limited Antibacterial therapeutics and prophylactics
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
EP3397641A1 (en) * 2015-12-29 2018-11-07 Immunetarget, Inc. 2h-chromeno[2,3-d]pyrimidine-2,4(3h)-diones as nf-kb inhibitors
CN109715625B (zh) 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
KR102537749B1 (ko) 2017-06-14 2023-05-26 산요 시키소 가부시키가이샤 안료 분산체 및 그것을 포함하는 착색 조성물
CN108191889B (zh) * 2018-01-11 2019-06-07 河南大学 1-(n-氧氟沙星酰胺基)-6-氟-7-哌嗪萘啶酮酸化合物及其制备方法和应用
CN107964020B (zh) * 2018-01-11 2019-07-05 河南大学 1-(n-左氧氟沙星酰胺基)-6-氟-7-哌嗪萘啶酮酸化合物及其制备方法和应用
WO2020036154A1 (en) 2018-08-13 2020-02-20 Otsuka Pharmaceutical Co., Ltd. Novel medicament for treating inflammatory bowel disease
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
US20230058189A1 (en) * 2019-02-08 2023-02-23 Frequency Therapeutics, Inc. Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same
CN110551124B (zh) * 2019-06-14 2021-01-08 山东省联合农药工业有限公司 一种喹诺酮类化合物或其农药学上可接受的盐及其制备方法与用途
CN112624970B (zh) * 2019-09-24 2022-10-28 南开大学 8位芳基取代喹啉氮氧化物在抗植物病毒及杀菌方面的应用
CN112870196B (zh) * 2019-11-11 2022-02-18 山东畜牧兽医职业学院 一种治疗耐药性微生物菌的组合物
JP2023012557A (ja) * 2020-02-10 2023-01-26 大塚製薬株式会社 新規肝性脳症治療剤
JP2023012559A (ja) 2020-02-10 2023-01-26 大塚製薬株式会社 新規炎症性疾患治療剤
JP2023012558A (ja) 2020-02-10 2023-01-26 大塚製薬株式会社 腸内細菌叢構成比率調整剤
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2023208172A1 (en) * 2022-04-29 2023-11-02 Beigene , Ltd. Substituted 7- (pyrimidin-4-yl) quinolin-4 (1h) -one compounds as cyclin dependent kinase inhibitors
AU2023308473A1 (en) * 2022-07-11 2025-02-20 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical compositions comprising a quinolone compound for irritable bowel syndrome
KR20250119608A (ko) * 2022-12-13 2025-08-07 오츠카 세이야쿠 가부시키가이샤 퀴놀론 화합물의 제조 방법
CN118255716A (zh) 2022-12-26 2024-06-28 深圳阿尔法分子科技有限责任公司 一种新型具有抗菌和抗癌功能的苯基喹诺酮类化合物及其制备
IL321669A (en) * 2022-12-26 2025-08-01 Alphamol Science Ltd Shanghai Novel phenylquinolone compound having antibacterial and anticancer functions, and preparation thereof
CN117402140B (zh) * 2023-10-13 2026-04-21 西南大学 喹诺酮吲哚类化合物及其制备方法和应用
WO2026044224A1 (en) * 2024-08-23 2026-02-26 Amgen Inc. Synthetic processes for pharmaceutically active compounds
CN121673221B (zh) * 2026-02-09 2026-06-19 浙江大学衢州研究院 一种喹诺酮化合物的制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5781486A (en) * 1980-11-10 1982-05-21 Otsuka Pharmaceut Co Ltd Benzo(ij)quinolidine-2-carboxylic acid derivative
JPS5872589A (ja) * 1981-10-28 1983-04-30 Dai Ichi Seiyaku Co Ltd ピリド〔1,2,3−de〕〔1,4〕ベンゾオキサジン誘導体
US4443447A (en) 1982-10-25 1984-04-17 Riker Laboratories, Inc. Phenyl-substituted tricyclic antibacterial agents
US4636506A (en) * 1984-12-06 1987-01-13 Pfizer, Inc. 7-heterocyclic-1,4-dihydroquinolones
ZA859283B (en) 1984-12-06 1987-07-29 Pfizer Substituted dihydroquinolone carboxylic acids and anti-bacterial compositions containing them
US4797490A (en) * 1984-12-06 1989-01-10 Pfizer Inc. Process for the preparation of 3-(2'-fluorophenyl)pyridine
US4623650A (en) * 1984-12-06 1986-11-18 Pfizer Inc. Antibiotic derivatives of 7-phenyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids
JPS62228063A (ja) * 1985-12-27 1987-10-06 Sankyo Co Ltd キノリンカルボン酸誘導体
IT1197841B (it) * 1986-10-14 1988-12-06 Mediolanum Farmaceutici Srl Derivati pirido-benzotiazinici ad attivita' antibatterica ed a lunga durata di azione
US4929613A (en) 1987-08-26 1990-05-29 Warner-Lambert Company Antibacterial agents
US5081254A (en) 1987-08-26 1992-01-14 Warner-Lambert Company Antibacterial agents
US5075319A (en) * 1987-09-08 1991-12-24 Sterling Drug Inc. Pyridinyl-quinolone compounds, their preparation and use
US4839355A (en) * 1987-09-09 1989-06-13 Sterling Drug Inc. Tricyclic-pyridinylquinoline compounds, their preparation and use
WO1989005643A1 (en) * 1987-12-18 1989-06-29 Pfizer Inc. Heterocyclic-substituted quinoline-carboxylic acids
DE3816119A1 (de) 1988-05-11 1989-11-23 Bayer Ag 7-substituierte chinolon- und naphthyridoncarbonsaeure-derivate
JPH0366301A (ja) 1989-08-03 1991-03-22 Asahi Corp 靴底射出成形金型
KR910009333B1 (ko) * 1989-10-23 1991-11-11 재단법인 한국화학연구소 항균작용을 갖는 퀴놀린계 화합물과 그의 제조방법
JP2613139B2 (ja) * 1990-07-19 1997-05-21 エスエス製薬 株式会社 キノロンカルボン酸誘導体
US5308843A (en) * 1990-09-11 1994-05-03 Sterling Drug Inc. Method of inhibiting mammalian topoisomerase II and malignant cell growth in mammals, with substituted (S)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4 ]-benzoxazine(and-benzothiazine)-6-carboxylic acids
EP0561850B1 (en) 1990-12-05 2000-07-12 NAEJA Pharmaceutical Inc. 7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid compounds useful as antibacterial agents
NZ290946A (en) * 1994-08-12 1997-12-19 Toyama Chemical Co Ltd Quinolone- or naphthyridone-carboxylic acid derivatives
JP3280388B2 (ja) 1997-06-26 2002-05-13 ドング ホワ ファーマシューチカル インダストリアル カンパニー,リミテッド キノロンカルボン酸誘導体
WO1999003465A1 (en) 1997-07-16 1999-01-28 Eisai Co., Ltd. Antibiotics containing indole derivatives
JP4370002B2 (ja) 1997-08-08 2009-11-25 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
ES2341509T3 (es) 1997-10-27 2010-06-21 Toyama Chemical Co., Ltd. Sal de un derivado de acido 7-isoindolino-quinoloncarboxilico, su monohidrato y composiciones que lo contienen como ingredientes activos.
ATE342897T1 (de) 1998-04-06 2006-11-15 Toyama Chemical Co Ltd Chinoloncarbonsäurederivate oder deren salze
JP2000229946A (ja) * 1998-12-10 2000-08-22 Toyama Chem Co Ltd キノロンカルボン酸の製造法およびその中間体
AU2325300A (en) * 1999-02-05 2000-08-25 Toyama Chemical Co. Ltd. Tricyclic quinolonecarboxylic acid derivatives or salts thereof
US20020049223A1 (en) * 1999-11-05 2002-04-25 Elmore Steven W. Quinoline and naphthyridine carboxylic acid antibacterials
DE10026903A1 (de) * 2000-06-03 2002-01-10 Cpc Cellular Process Chemistry Verfahren zur Herstellung von Chinolon-3-carbonsäuren
WO2002009758A2 (en) * 2000-08-01 2002-02-07 Wockhardt Limited Inhibitors of cellular efflux pumps of microbes
JP2003104988A (ja) * 2001-09-28 2003-04-09 Sato Pharmaceutical Co Ltd 抗菌剤として有用なキノロン誘導体
US7012144B2 (en) 2001-12-31 2006-03-14 Korea Research Institute Of Chemical Technology Quinolone carboxylic acid derivatives
JP3885679B2 (ja) * 2002-06-28 2007-02-21 株式会社日立製作所 電子機器
US20070224282A1 (en) * 2005-03-28 2007-09-27 Toyama Chemical Co., Ltd. Fine Dispersion of Sparingly Soluble Drug and Process for Producing the Same
CA2615089C (en) * 2006-02-17 2015-11-17 Morinaga Milk Industry Co., Ltd. Method for detection of microorganism and kit for detection of microorganism
CN101168541A (zh) * 2006-10-26 2008-04-30 孙飘扬 喹诺酮羧酸类衍生物及其制备方法和药物用途
US8124623B2 (en) * 2006-11-10 2012-02-28 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
US20090270379A1 (en) * 2008-04-23 2009-10-29 Macielag Mark J Quinolone derivatives useful as antibacterial agents
EP2177214A1 (en) * 2008-10-17 2010-04-21 Ferrer Internacional, S.A. Solid Oral Dosage Forms and Uses
HRP20180483T1 (hr) * 2011-08-31 2018-05-04 Otsuka Pharmaceutical Co., Ltd. Spoj kinolona

Also Published As

Publication number Publication date
US20210032207A1 (en) 2021-02-04
US20190077762A1 (en) 2019-03-14
JP2018150324A (ja) 2018-09-27
JP6039025B2 (ja) 2016-12-07
EA201890098A2 (ru) 2018-05-31
LT2751083T (lt) 2018-03-26
WO2013029548A1 (en) 2013-03-07
AU2012303954A1 (en) 2014-02-20
KR101996697B1 (ko) 2019-07-04
IL230559B (en) 2019-03-31
MX376109B (es) 2025-03-07
KR101560073B1 (ko) 2015-10-13
JP2016027046A (ja) 2016-02-18
HK1216528A1 (zh) 2016-11-18
MX371361B (es) 2020-01-27
BR112014000665B1 (pt) 2020-02-18
JP2014525420A (ja) 2014-09-29
AU2012303954B2 (en) 2017-06-22
BR112014000665A2 (pt) 2017-01-10
EA201890098A3 (ru) 2018-09-28
CN105017151A (zh) 2015-11-04
EA030867B1 (ru) 2018-10-31
EP2751083B1 (en) 2017-12-27
KR20140139132A (ko) 2014-12-04
EP3318557A2 (en) 2018-05-09
US9067887B2 (en) 2015-06-30
DK2751083T3 (en) 2018-02-26
US20200055823A1 (en) 2020-02-20
MX394239B (es) 2025-03-24
US20150239865A1 (en) 2015-08-27
SG10201606932TA (en) 2016-10-28
NZ620447A (en) 2016-02-26
EP2751083A4 (en) 2015-06-10
HK1252389A1 (en) 2019-05-24
PH12014500130A1 (en) 2014-02-24
CY1120066T1 (el) 2018-12-12
JP6106174B2 (ja) 2017-03-29
SG2014004162A (en) 2014-03-28
EP3318557A3 (en) 2018-07-11
PL2751083T3 (pl) 2018-08-31
US9440951B2 (en) 2016-09-13
SI2751083T1 (en) 2018-04-30
AU2017203756A1 (en) 2017-06-22
CO6920292A2 (es) 2014-04-10
JP2017039733A (ja) 2017-02-23
KR20130095831A (ko) 2013-08-28
ZA201402326B (en) 2016-06-29
CN103764631B (zh) 2017-02-15
EA034787B1 (ru) 2020-03-20
NO2751083T3 (cg-RX-API-DMAC10.html) 2018-05-26
AU2017203756B2 (en) 2019-02-07
PT2751083T (pt) 2018-03-05
CN105712976A (zh) 2016-06-29
TW201319053A (zh) 2013-05-16
TW201718506A (zh) 2017-06-01
IL230559A0 (en) 2014-03-31
KR20140087059A (ko) 2014-07-08
US20140179675A1 (en) 2014-06-26
US20150005287A2 (en) 2015-01-01
TWI606044B (zh) 2017-11-21
HK1226077A1 (zh) 2017-09-22
SG10201505811QA (en) 2015-09-29
MX2019010100A (es) 2019-10-15
MX2014002338A (es) 2014-03-27
CA2845459C (en) 2019-08-27
TWI583680B (zh) 2017-05-21
CA2845459A1 (en) 2013-03-07
EP2751083A1 (en) 2014-07-09
HRP20180483T1 (hr) 2018-05-04
HK1198828A1 (en) 2015-06-12
EA201490530A1 (ru) 2014-06-30
PH12014500130B1 (en) 2018-07-04
US20170362180A1 (en) 2017-12-21
HUE036301T2 (hu) 2018-06-28
ES2660973T3 (es) 2018-03-26
TW201630900A (zh) 2016-09-01
AR087747A1 (es) 2014-04-16
MY165004A (en) 2018-02-28
US20160340314A1 (en) 2016-11-24
CN105017151B (zh) 2019-04-02
CN103764631A (zh) 2014-04-30

Similar Documents

Publication Publication Date Title
PH12014500130B1 (en) Quinolone compound
BR112012014858A2 (pt) agente antiplaqueta
BR112014010628A2 (pt) compostos pesticidas
BR112015001121A2 (pt) composição para controle de doença de planta e aplicação para a mesma
BR112014007078A2 (pt) composição de controle de doença de plantas e seu uso
UA110647C2 (uk) Похідне азолу, спосіб його одержання, проміжна сполука і хімічний агент, призначений для застосування в сільському господарстві і садівництві, і агент для захисту промислових матеріалів
BR112012013201A2 (pt) derivado de azol, composto intermediário, métodos para produzir o derivado de azol e o composto intermediário, e, agente de agro-horticultura ou um agente protetor de material industrial.
BR112017009168A2 (pt) derivado de tionucleosídeo ou sal deste e composição farmacêutica
NZ716840A (en) Combination formulation of two antiviral compounds
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
BR112016007427A2 (pt) compostos de pirazol-amida e usos dos mesmos
PH12014500759A1 (en) 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
BR112015023829A2 (pt) composto de amidina e seu uso
BR112012027387A2 (pt) composição para controle de doenças de plantas e uso da mesma
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
CO6571879A2 (es) Composición de control de fitoenfermedades y su uso
BRPI0713743C1 (pt) composto, e, composição farmacêutica
BR112015020222A8 (pt) composto de azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas
BR112012014196A2 (pt) agente para prevenir ou melhorar a pigmentação
BR112016011778A8 (pt) pirazol fluorofenila, seus usos, e composição farmacêutica
BR112013030570A2 (pt) agente para o controle de ectoparasitas de animais
MX2010004405A (es) Derivados de pirrolo [1,2-c] imidazol para utilizarse en la profilaxis o tratamiento de cancer que es refractario a terapias cancerigenas conocidas.
BR112012012948A2 (pt) processo para a preparação de derivados de cicloexano
TH156794A (th) สารประกอบควิโนโลน

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2563 DE 18/02/2020, QUANTO AO ITEM (72) NOME DO INVENTOR.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2790 DE 25-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.